Episode

Hairy Cell Leukemia: Strategies for Improved Patient Outcomes

Podcast: Treating Blood Cancers
Published: Nov 20, 2025
Duration seconds: 2410
Processing state: not_requested
Canonical source: https://treatingbloodcancers.org/e109/?utm_source=rss&utm_medium=rss&utm_campaign=e109
Audio: https://media.blubrry.com/treating_blood_cancers/content.blubrry.com/treating_blood_cancers/TBC_E109-Dr_Hampel-HCL_mixdown_Production.mp3
JSON: /v1/public/podcasts/treating-blood-cancers-14318/episodes/hairy-cell-leukemia-strategies-for-improved-patient-outcomes
Markdown: /podcast/treating-blood-cancers-14318/hairy-cell-leukemia-strategies-for-improved-patient-outcomes.md

Actions

POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/hairy-cell-leukemia-strategies-for-improved-patient-outcomes/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/treating-blood-cancers-14318/hairy-cell-leukemia-strategies-for-improved-patient-outcomes.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.